Oral Presentation: Five Hematologic Malignancies Studies by Leads Biolabs to Be Featured at ASH 2025
NANJING, China, Nov. 4, 2025 /PRNewswire/ -- Leads Biolabs (Stock Code: 9887.HK) today announced that five research abstracts from its hematological oncology portfolio—including programs LBL–034 and LBL–076—have been accepted for presentation at the...
Breakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session
NANJING, China, May 31, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs") today announced the presentation of groundbreaking clinical data from a multicenter phase Ib/II clinical trial evaluating LBL-024, an anti-PD-L1/4-1BB...
Bioheng Therapeutics Announces FDA Clearance of IND Application for CD7 UCAR T Cell Therapy in T-ALL/LBL
BOSTON, March 5, 2025 /PRNewswire/ -- Bioheng Therapeutics US LLC ("Bioheng"), a clinical-stage biotech company dedicated to developing innovative universal CAR-T cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Granted Orphan Drug Designation of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs, for Treatment of Neuroendocrine Cancer
NANJING, China, Nov. 22, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by the company with global...